Shop by goal

  • Metabolic Signalling
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • All compounds →
  • Popular compounds

  • BPC-157
  • TB-500
  • GHK-Cu
  • Retatrutide
  • Semaglutide
  • Ipamorelin
  • All bestsellers →
  • Research resources

  • Research Areas
  • Certificates of Analysis
  • Research Glossary
  • Compare Compounds
  • Peptide Guides
  • Delivery Guide
  • Track Order
  • Recently viewed

  • All peptide guides
  • Crypto Blog
  • How to Reconstitute
  • Reconstitution Calculator
  • How to Store
  • Research
  • Certificates of Analysis
  • Sign In
  • Create Account
  • My Account
  • My Orders
  • My Referrals
  • Log Out
  • Track Order
  • Refer a Friend
  • Follow us on Twitter/X
  • How-to guides

    Semaglutide vs Tirzepatide: the receptor-pathway difference, plainly

    Educational pathway discussion, no human-use angle. The headline distinction in the literature: semaglutide is a GLP-1 receptor agonist; tirzepatide engages both GLP-1 and GIP receptors (a dual agonist). Retatrutide goes further as a triple agonist.

    What I find under-explained for newcomers is why "more receptors" is an active research question rather than an automatic "better." Anyone have a good review paper that lays out the incretin pathways without assuming a pharmacology degree? Let's build a reading list.

    Clear summary. The "more receptors ≠ automatically better" point is the right one to stress — the dual- and triple-agonist work is an open research question, not a settled ranking. For a non-specialist start, look for incretin-pathway review articles rather than primary trial papers.

    Adding to the reading list: the GIP side is genuinely under-appreciated in casual write-ups. People hear "GLP-1 plus something" and skip what GIP signalling actually contributes. A good GIP review pairs well with this.

    This is the cleanest plain-English version of the distinction I've seen. The receptor-engagement framing (single / dual / triple) is going straight into my notes.

    Love that the thread stayed firmly on mechanism. Compiling the cited reviews into the top post so newcomers get the pathway map without the noise.

    New here and this is the cleanest single/dual/triple-agonist explanation I've read. Saved the cited reviews. The "more receptors isn't automatically better" point is the bit most write-ups skip.

    Want to join the discussion?

    Related reading

  • GLP-1 peptide guides
  • Metabolic research compounds
  • PRECISION. PURITY. PERFORMANCE.

    Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

    Shop

  • All research compounds
  • Price list
  • Where to buy peptides
  • Compare compounds
  • Compare vial sizes
  • Affiliate programme
  • Research

  • Peptide 101
  • Published COAs
  • Research areas
  • Research blog
  • How-to guides
  • Peptide guides
  • Research glossary
  • Support

  • Track your order
  • Contact us
  • Shipping & delivery
  • FAQ
  • Community forum
  • Customer reviews
  • Refund policy
  • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • PayPal
  • Cryptocurrency
  • Cash App
  • Card payments
  • Bank transfer (SEPA)
  • Paying with crypto
  • Live crypto prices
  • Shop by goal

  • Metabolic Signalling
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • Shop by compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Semaglutide
  • CJC-1295 (without DAC)
  • Ipamorelin
  • MOTS-C
  • All compounds →
  • Shop by region

  • United Kingdom
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • United States
  • Northern Ireland
  • Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    © 2026 New-U Research Compounds · new-u.io

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.